<DOC>
	<DOCNO>NCT02358629</DOCNO>
	<brief_summary>Trial evaluate safety performance NovaCross™micro-catheter respect provide additional guidewire support expect allow easy cross femoropopliteal infra-popliteal Chronic Total Occlusion ( CTO ) lesion . The procedure conduct patient diagnose CTO peripheral vessel require revascularization .</brief_summary>
	<brief_title>A Prospective , Non-randomized Study Evaluate Safety Performance NovaCross™ Microcatheter Femoropopliteal Chronic Total Occlusion ( CTO ) .</brief_title>
	<detailed_description>This open label , single center , prospective , first man pilot study investigational device , NitiLoop micro-catheter , test 15 patient symptomatic peripheral arterial occlusive disease schedule undergo CTO anterograde approach .</detailed_description>
	<criteria>1 . Adult age 2580 2 . Patient understands sign study inform consent form . 3 . Patient symptomatic peripheral artery disease ( PAD ) require endovascular revascularization CTO , evidence angiography , compute tomography magnetic resonance angiography . 4 . Patient occlude femoropopliteal infra popliteal artery 5 . Target femoropopliteal infrapopliteal vessel ≥ 2.5 mm ≤5 mm diameter . 6 . Patient RutherfordBecker Classification 25 . 1 . Patient unable give inform consent . 2 . Current participation another study investigational drug device . 3 . Patient known sensitivity allergy contrast material adequately pretreated . 4 . Patient known sensitivity allergy antiplatelet medication . 5 . Patient pregnant lactating . 6 . Patient coexist disease medical condition contraindicate percutaneous intervention . 7 . Target lesion bypass graft . 8 . Target lesion stent ( i.e. , instent restenosis ) . 9 . Patient procedure target limb within 7 day . 10 . Patient undergone attempt treatment CTO within prior 3 month ( prevent guidewire enter dissection plane create prior recanalization attempt . 11 . Vasculitis Buerger disease ( thrombendarteritis obliterans ) 12 . Evidence embolism 13 . Peripheral vessel aneurysm</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>